Skip to main content
. 2022 Jun 29;13:3731. doi: 10.1038/s41467-022-31500-3

Fig. 7. Investigation of the anti-infective efficacy of TTCT in vivo.

Fig. 7

A Survival rates of acute KPN-infected and (B) TRKP-infected mice with pneumonia treated with TIG, TCT, TTCT, or Ts-TPGS/Cap nanorods for 5 days (n = 6 mice per group). Mice with pneumonia treated with saline were used as a negative control. C WBC and D neutrophil counts in blood samples from mice with pneumonia receiving various preparations (n = 5 mice for each group). E Total cell counts and F neutrophil percentages in BALF obtained from KPN- and TRKP-infected mice with pneumonia administered different preparations (n = 3 mice for each group). G Flow cytometry results of anti-Ly-6G/Ly-6C and anti-CD11b double-stained cells obtained from the BALF of mice with pneumonia. Double-positive cells represented neutrophils in BALF. H Levels of CRP in the BALF of mice with pneumonia after different treatments (n = 6 mice for each group). I Representative KPN and TRKP bacterial colonies formed on LB agar plates from the BALF of mice with pneumonia receiving various treatments. TIG free tigecycline, TIG(L) low dose of tigecycline (15 mg/kg), TIG (H) high dose of tigecycline (45 mg/kg), TCT tigecycline loaded TPGS/Cap nanorods, TTCT tigecycline-loaded Ts-TPGS/Cap nanorods, KPN Klebsiella pneumonia, TRKP tigecycline-resistant Klebsiella pneumonia. Data are presented as the mean ± SD. Log-rank (Mantel-Cox) test was performed in A and B. One-way analysis of variance (ANOVA) with post hoc Tukey tests were performed in C, D, E, F, and H. Source data are provided as a Source Data file.